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The current emphasis on translational research is starting to blur differences between research 
environments in academia and industry. This has opened up a two-way street for academic 
researchers to go to work in industry and, in some cases, to then return to academia.Earlier this year, cell biologist Ira Mell-
man traded a house on five acres and 
a tenured position at Yale University 
for the ups-and-downs of city living in 
San Francisco and a job at Genentech. 
This might seem a surprising move for 
someone so entrenched in academia, 
but Mellman follows in the footsteps 
of other well-known scientists who 
have made the jump to industry, nota-
bly Philip Needleman, Marc Tessier- 
Lavigne, Roger Perlmutter, Dennis 
Choi, and Roy Vagelos, among others.
Going from academia to industry 
(and less commonly, the other way) is 
nothing new, of course. But a squeeze 
in funding for academic laboratories, 
the creation of quasi-university-like 
research organizations by big pharma, 
and PhD and postdoctoral students 
educated in an environment where 
applied research is more common 
have contributed to lowering the bar-
rier to making the switch. According to 
Charlene Ledbetter of LedbetterSte-
vens, a life sciences executive search 
firm in New York, “10 to 30 percent 
more senior roles [in industry] are being 
filled by academics than 10 years ago.” 
These, says Ledbetter, are senior sci-
entists with tenure moving into top 
positions at biopharma companies.
At the same time, research institu-
tions funded by big pharma—such as 
Merck’s department of experimental 
medicine in Rahway, New Jersey and 
the Genomics Institute of the Novar-
tis Research Foundation (GNF) in San 
Diego—are forming a bridge between 
research in academia and industry. 
GNF, for example, strives to combine 
for-profit resources with hiring from 
academia, a relatively flat person-
nel structure, and encouragement to 
publish, says Peter Schultz, GNF’s 
director and a faculty member at The 
Scripps Research Institute in La Jolla, 
California.A Blurring of Differences
“The dividing lines between industry 
and academia have become progres-
sively more porous,” says Dennis 
Choi, executive director of the Com-
prehensive Neuroscience Initiative at 
Emory University in Atlanta, Georgia. 
“There’s a blurring of those careers,” 
making it not only more accepted to 
go from academia to industry, but 
also back again, he says. Choi has 
already been down this two-way 
street. Before taking up his post at 
Emory two months ago and after a 
stint at Boston University as a pro-
fessor of pharmacology and experi-
mental therapeutics, Choi had been 
executive vice president for neuro-
science at Merck Research Labo-
ratories in West Point, Pennsylvania 
for five years. Prior to joining indus-
try, he was head of the neurology 
department at Washington University 
Medical School in St. Louis and was 
director of the McDonnell Center for 
Cellular and Molecular Neurobiology. 
“My time in industry was regarded 
as an asset” by academic recruiters, 
says Choi. “My direct understanding 
and appreciation of what is required 
in development of drugs is viewed as 
helpful by my colleagues.”
“In the Bay Area, it is totally cultur-
ally acceptable to go from academia 
to biopharma and back. It’s quite nor-
mal, actually, lots of people do both,” 
says Frank McCormick, director of 
the University of California, San Fran-
cisco Comprehensive Cancer Center 
and Cancer Research Institute and a 
professor in the department of micro-
biology and immunology. McCormick 
himself embodies that path, having 
previously served as the chief scien-
tific officer of Onyx Pharmaceuticals, 
which he founded, and as vice presi-
dent for research at both Chiron Cor-
poration and Cetus. “The quality of Cell 131, Ocscience is so high [in both academia 
and industry] that one’s peers recog-
nize it as perfectly acceptable to do,” 
says McCormick.
Patrick Griffin, chair of molecular 
therapeutics and director of trans-
lational research at Scripps Florida 
(a division of The Scripps Research 
Institute), agrees. “I think it’s not a 
clear distinction between academic 
and for-profit at Scripps,” he says. 
There is a “need for good commu-
nications skills and leadership, you 
have to be doing cutting edge sci-
ence in all cases.” Originally, he made 
the decision to leave academia after 
getting his doctorate at the Univer-
sity of Virginia working in proteomics. 
I was “thinking I wasn’t cut out for 
academia. My impression was you 
spent a lot of time writing grants and 
papers, not enough time in the lab.” 
He first went to Genentech; “I was a 
scientist, a real live job, but the salary 
and cost of living in South San Fran-
cisco were not compatible.” He then 
switched to the California Institute of 
Technology to work on mass spec-
trometry systems biology with Lee 
Hood. That led to a collaboration and 
eventually a full-time job with Merck 
in their immunology division.
“When I left to go from Harvard 
to Millennium, enough people ques-
tioned my sanity, I was a Howard 
Hughes investigator at Harvard, why 
would I leave that?” says Geoffrey 
Duyk, now a San Francisco-based 
healthcare investor and partner in 
the investment firm TPG (formerly 
the Texas Pacific Group). “Access to 
genomics tools was an uphill battle 
at Harvard at that moment in time” in 
the early ‘90s, he says. “The private 
sector was willing to invest, I went 
for the tools.” Duyk, an MD/PhD, in 
addition to being on the founding 
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ceuticals in Cambridge, MA has since 
served as president of research and 
development at Exelixis in South San 
Francisco. “I’ve been able to move 
between these communities and act 
as a peer. I’m more of an entrepre-
neurial scientist than anything else,” 
says Duyk.
Patrick Vallance, now head of drug 
discovery at GlaxoSmithKline (GSK) 
in London, UK, was formerly chief 
of the department of medicine at 
University College London and was 
tapped for an industry position after 
serving on GSK’s research advisory 
board for two years. He acknowl-
edges that some academics consider 
a move to industry as selling out, but 
he says that is changing. And he has 
been “incredibly invigorated, ideas I 
haven’t thought about for a long time” 
are bubbling to the surface. It has 
taken “me right outside my comfort 
zone, gave me a buzz that once again 
I would be challenged.”
But Still a Cultural Divide
For all the movement back and forth 
between academia and industry, 
there remain significant differences 
between the two environments and 
in the kind of people who thrive in 
one place or the other. “If we went 
back and looked at top people’s CVs, 
people who lead R&D commercial 
organizations, what would be their 
biomarkers?” asks Charlene Ledbet-
ter of LedbetterStevens. Her answer: 
“Howard Hughes investigators, a 
member of the National Academy of 
Sciences, other key scientific awards, 
a willingness to learn, and the ability 
to build teams rather than be a sole 
contributor.” Choi echoes the impor-
tance of being a team player “You 
basically think more in terms of ‘we,’ 
you redefine ego to encompass team, 
you can only succeed in industry as a 
team,” he says.
And, say people who have suc-
cessfully made the transition, aca-
demics joining pharma need to tuck 
away their egos. “It’s very easy to 
believe, if you’re a success in any-
thing, that you can develop a drug by 
the metric ton instead of micrograms 
at a lab bench,” says Joseph Milet-
ich, senior vice president of research 212 Cell 131, October 19, 2007 ©2007 Elsand development at Amgen in Thou-
sand Oaks, California. “But unless 
you actually work at it for a while, you 
don’t understand how complicated it 
is, no matter where you come from. 
If you can’t sit in a room and admit 
to someone else that they know more 
than you, you aren’t going to make 
it” in industry, says Miletich, who 
was also senior vice president for 
worldwide preclinical development at 
Merck as well as chief of the division 
of laboratory medicine at Washington 
University Medical School.
Whether you are a researcher in 
academia connected with trans-
lational research or “a doctor in a 
medical center and then go over to a 
Pfizer, you may be leading a medical 
team, but the business people have 
all the power. That is a huge adjust-
ment, and for some, a narcissistic 
blow,” explains Kerry J. Sulkowicz, 
a clinical professor of psychiatry at 
NYU Medical Center and founder of 
the Boswell Group, a consulting firm 
focusing on the psychology of busi-
ness for CEOs and other business 
leaders. “The rewards of [industry] 
work are promotion and financial. 
Academia tends to be much more 
intellectual. For academics, whether 
scientists or clinicians, the more 
they can see themselves as business 
people, albeit with [a science] back-
ground, the more successful they will 
be. When they start to work for Pfizer, 
they will be, first and foremost, busi-
ness people.”
Collaborative processes as well as 
milestones, project plans, and go/
no-go decisions are not typical in the 
academic setting, points out Giulio 
Superti-Furga, scientific director of 
the Research Center for Molecular 
Medicine of the Austrian Academy of 
Sciences in Vienna. Superti-Furga, 
who spent a year at Genentech as a 
PhD student before becoming a staff 
scientist and team leader at the Euro-
pean Molecular Biology Laboratory in 
Heidelberg, is cofounder of the bio-
tech company Cellzome. “You need a 
higher degree of social competence 
in the industry setting,” he says. Also, 
you are up against a bias from current 
employees. “There is a certain skepti-
cism in the pharma setting for people evier Inc.coming from academia,” says Super-
ti-Furga. “Industrial researchers need 
to give people who come from aca-
demics some time to learn.”
Neuroscientist Marc Tessier-Lavi-
gne, who became senior vice presi-
dent of research drug discovery at 
Genentech in 2003, consulted for 
companies while a Howard Hughes 
investigator at Stanford University. 
But, he says, it’s “not the same thing as 
doing it, as being inside. There was a 
learning curve on the research side, in 
translation,” he recalls of first going to 
Genentech. “And learning about drug 
discovery and development, what 
makes a good drug… I was thrown in 
the deep end, sink or swim, but given 
a lot of help and mentoring.”
There are also other aspects of the 
transition to industry that take some 
getting used to for senior researchers 
immersed in the academic environ-
ment. “When you go into industry, your 
public record is diminished,” points out 
Philip Needleman, who spent 25 years 
at Washington University School of 
Medicine as a professor and chairman 
of the department of pharmacology 
before becoming senior vice president 
of Monsanto and president of Searle 
Research and Development. “You are 
no longer on study sections. In indus-
try, you have meetings for decisions, 
not discussion. I forgot how academia 
is so Talmudic.”
But industry is not for everyone. 
Nathanael S. Gray was at GNF in 
San Diego for more than seven years 
before moving to the Dana Farber 
Cancer Institute in Boston as an 
assistant professor. He says he was 
getting too removed from the bench. 
“Most pharmas have two tracks: man-
agement and a scientific ladder track. 
If you want to grow, you pretty much 
need to take the management track, 
and pushed away from science, it 
becomes personnel management. I 
wanted to stay closer to the science,” 
he says. Gray, who works on kinase 
inhibitors relevant to oncology at 
Dana Farber, says he has brought his 
experiences and contacts from indus-
try to his new position. “For me, it was 
a very valuable experience, it was a 
start-up environment which had the 
resources of Novartis. There are a 
large number of people you meet and 
rub shoulders with. In academia, it is 
more cloistered.”
Roy Vagelos, former CEO of Merck, 
tells the story of two top research-
ers at the company who eventually 
returned to academia. It hadn’t been 
their scientific acumen or, necessar-
ily, their rate of making significant 
discoveries. “The difference with 
those folks,” says Vagelos, was that 
“they never got the bug that I went 
to Merck with, that drug discovery is 
the most important thing you can do 
in your life.”
Making the Leap
Genentech has been particularly suc-
cessful in recruiting top academic 
researchers, including most recently 
Ira Mellman, to work at its headquar-
ters in South San Francisco. This is 
partly because Genentech has cre-
ated an environment where academ-
ics feel at home. “I was intrigued 
enough to take the position realizing 
I could have my cake and eat it too,” 
says Vishva Dixit, a vice president 
and staff scientist at Genentech. 
(Dixit was lured to the company 10 
years ago from his tenured position 
at the University of Michigan Medical 
School.) “I could continue to run my 
own research program while contrib-
uting to” translational research at the 
company, says Dixit.
The ability of academic research-
ers to move to Genentech with their 
labs is a major asset. Points out Mell-man, “I took my lab…, one part of 
my existence is still defined by that, 
being a basic scientist, addressing 
fundamental questions in the labora-
tory.” “If you give up a lab, participa-
tion changes with the international 
community of scientists, you don’t 
control your own research position,” 
he says. But having a lab means that 
you need to publish your research. 
Mellman says that at Genentech 
while research is vetted for proprie-
tary or possible trade secrets prior to 
submission to a journal, publication is 
encouraged.
Another example of the academic 
aspect to Genentech is their post-
doctoral fellows program run by Dixit, 
which currently has about 100 post-
docs. In this program “the funding is 
guaranteed for four years, they are 
free to work on anything they want 
with their mentors, as long as it is 
cutting edge research and they pub-
lish, …[and they are] not allowed to 
work on a product-related project,” 
says Dixit. After four years in the pro-
gram, on average about 10 percent 
of postdocs get hired by Genentech, 
10 percent go back to academia, and 
80 percent go to other jobs or law 
school, etc., he says. But aside from 
being a potential employee pool, the 
postdoctoral program also helps to 
lure leading academics to the cam-
pus. “I was invited to Genentech by 
postdocs to do a seminar,” says Ira 
Mellman. “I ran into an old friend, 
Richard Scheller.” (Scheller, executive Cell 131, Ocvice president of research at Genen-
tech, used to be an HHMI investigator 
at Stanford.) “We talked, he started a 
process of trying to convince me to 
come here.”
For Mellman, who was scientific 
director of the Yale Comprehensive 
Cancer Center, the offer struck a nerve. 
His mother had died of ovarian can-
cer, and recently his lab manager from 
Yale also died of the disease. When 
she was diagnosed, Mellman recalls 
his wife saying to him, “if you guys are 
so smart, why can’t you do something 
to help her?” “Why indeed?” says 
Mellman. “It almost becomes a moral 
obligation to do it.”
And, by this time, he had shed any 
illusions about academic research. 
“Once you become a PI you say you 
have great academic freedom, on 
paper it’s true, but in reality you don’t,” 
says Mellman. “You’re not free, you’re 
a slave to your own success… You 
need to keep building on your base to 
keep grant renewals. It’s an illusion to 
think you are completely unfettered. 
You can’t wake up and decide to work 
on worms, in two years when grants 
are due you would be laughed out of 
study sections.”
A major difference for him between 
life in academia and in industry at 
Genentech, he says, is that “in aca-
demia you can be a success by being 
interesting. Here, it is assured that 
you are interesting, but you have to 
be useful. It’s a different kind of intel-
lectual challenge.”
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